Skip to content

Study of the Analgesic Effect of the Perineal Infiltration of Ropivacaine 0.75% Versus Placebo in Post-episiotomy Perineal Pain

Study of the Analgesic Effect of the Perineal Infiltration of Ropivacaine 0.75% Versus Placebo in Post-episiotomy Perineal Pain: a Randomized, Double-blind Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03084549
Acronym
ROPISIO
Enrollment
272
Registered
2017-03-21
Start date
2017-10-24
Completion date
2020-11-04
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episiotomy

Brief summary

Episiotomy is a common obstetric gesture (20 to 30% of deliveries by the low route). In postpartum, perineal pains associated with episiotomy are common, about 70% on D7 and persistent 13% at 5 months. Most studies of obstetrical analgesia have focussed on pain during labor or following a caesarean section. The perineal pain associated with the realization of an episiotomy has been much less studied and often undervalued. Local ropivacaine has shown its effectiveness in the reduction of postoperative pain in many indications (wall surgery, hemorrhoidectomy, infiltration of trocar scars during laparoscopy). This product has the advantage of being well tolerated, easy access and administration. Three recent studies compared the post-episiotomy analgesic efficacy of local ropivacaine versus lidocaine versus placebo and lidocaine versus no infiltration. Two of these studies showed statistically significant results. However, they focused on the results at 24 and 48 hours and did not evaluate the analgesic efficacy in the medium and long term.

Interventions

Administration of placebo in the margins of the episiotomy

DRUGAdministration of Ropivacaïne

Administration of Ropivacaïne in the margins of the episiotomy

Sponsors

Centre Hospitalier Departemental Vendee
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major Patient (≥ 18 years) * Term ≥ 37 weeks of amenorrhea * Right medio-lateral episiotomy performed for medical need * Delivery of a single fetus in a cephalic presentation with or without instrumental extraction * Delivery under epidural anesthesia * Patient to be monitored over 6 months of study * Patient in ability to understand protocol * Patient having given consent and signed informed consent * Patient with social coverage

Exclusion criteria

* Hypersensitivity or known allergy to Ropivacaine or to other amide-linked local anesthetics or to any of the excipients * General contraindication specific to local anesthesia, irrespective of the local anesthetic used * Contraindication for Ropivacaine- Obstetric paracervical anesthesia * Hypovolemia * Weight \<50 kg * Contra-indication or refusal of the epidural * Poor understanding of the French language * Substance addiction. * Chronic pain syndrome. * Severe hepatic or renal impairment. * Acute porphyria. * Caesarean section programmed. * Tear of the 3rd degree according to the associated French classification. * Refusal to participate in the study * Patient under tutelage, curatorship, or deprived of liberty

Design outcomes

Primary

MeasureTime frameDescription
Compare the analgesic efficacy of ropivacaine 75 mg infusion versus placebo (physiological saline) in patients with right mid-lateral episiotomy during postpartum D7 delivery.7 days after episiotomyDigital pain scale

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026